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Abstract
Introduction: The therapeutic effect of radioactive iodine (131I) on benign goitre consists of the emission of tissue-destructive beta-radiation. 
Since the range of beta 131I radiation in tissue can reach 2.4 mm, it can affect the adjacent parathyroid glands. The purpose of this paper 
is to assess parathyroid function in patients with toxic and non-toxic goitres, up to five years following 131I therapy. 
Material and methods: The study sample consisted of 325 patients with benign goitres (220 with toxic nodular goitre (TNG), 25 with 
non-toxic nodular goitre (NTNG), and 80 with Graves’ disease (GD) treated with 131I. The therapeutic activity of 131I for each patient was 
calculated using Marinelli’s formula. The serum levels of fT3, fT4, TSH, iPTH and Ca
2+, Ca and phosphates were determined one week before 
131I administration, as well as every two months up to a year following the therapy, and then after three and five years post-treatment. 
Results: After two months following the administration of 131I, all the treated patients showed a statistically significant above normal increase 
in iPTH concentrations (amounting to a value almost twice the norm in patients with TNG), which remained stable up to ten months 
after treatment, to return to normal level in the following months. In all the patients, Ca2+, Ca, phosphates concentration remained within 
normal range throughout the course of the study. The concentrations of fT3 and fT4 quickly returned to normal after 
131I administration, 
and remained within normal range until the completion of the study. 
Conclusion: Radioiodine treatment of benign thyroid disorders results in transient (up to ten months after 131I administration) hyperpar-
athyroidism. The condition does not influence the level of calcium and phosphates concentration in any significant way. 
(Endokrynol Pol 2013; 64 (5): 340–345)
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Streszczenie
Wstęp: Efekt terapeutyczny radiojodu (131I) w wolu łagodnym opiera się na emisji niszczącego tkanki promieniowania beta. Maksymalny 
zasięg promieniowania beta 131I w tkance wynosi do 2,4 milimetra. Dlatego, też w zasięgu tego promieniowania mogą się znajdować 
sąsiadujące z tarczycą przytarczyce. Celem pracy była ocena czynności przytarczyc u chorych z wolem nadczynnym i normoczynnym 
poddanych terapii 131I w okresie do 5 lat od zastosowanego leczenia.
Materiał i metody: Badania zostały wykonane u 325 chorych z łagodnym wolem (220 z wolem guzowatym nadczynnym (TNG), 25 
z wolem guzowatym obojętnym (NTNG) i 80 z chorobą Gravesa-Basedowa (GD) poddanych leczeniu 131I. Aktywność lecznicza 131I 
dla każdego pacjenta wyliczana była z wzoru Marinellego. W trakcie radiojodoterapii oznaczano stężenia fT3, fT4, TSH, iPTH, Ca
2+, Ca 
i fosforanów w surowicy tydzień przed podaniem 131I, i następnie w odstępach dwumiesięcznych przez rok po terapii oraz po 3 i 5 latach. 
Wyniki: U wszystkich chorych po 2 miesiącach od momentu rozpoczęcia leczenia zaobserwowano znamienny statystycznie wzrost stę-
żenia iPTH ponad normę (do wartości prawie dwukrotnie powyżej normy u pacjentów z TNG), który utrzymywał się aż do 10 miesiąca, 
a następnie ulegał normalizacji. Stężenia Ca2+, Ca i fosforanów u wszystkich leczonych pozostawały w zakresie normy w trakcie całego 
badania. Stężenia fT3 i fT4 w surowicy po podaniu 
131I szybko się normalizowały i pozostawały w zakresie normy do końca badania.
Wnioski: Radiojodoterapia łagodnych schorzeń tarczycy prowadzi do powstania przejściowej (trwającej maksymalnie do 10 miesiąca od 
podania radiojodu) nadczynności przytarczyc. Stan ten istotnie nie wpływa na stężenia wapnia i fosforanów w surowicy. 
(Endokrynol Pol 2013; 64 (5): 340–345)
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Introduction 
It is widely known that the therapeutic effect of the 
radioiodine isotope 131I for both non-toxic and toxic 
goitres is based on the fact that it emits strong ionising 
beta radiation, which causes damage to thyrocytes. As 
is known from physics, the maximum range of beta 
radiation from 131I decay is 2.4 mm [1–3]. That is why 
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radiation affects not only the thyroid gland tissue but 
also reaches over 2 mm beyond it, and its effect increases 
with the magnitude of radiation dose. It is known from 
anatomy and histology that parathyroid glands are 
situated in the immediate vicinity of the thyrocytes, 
on the posterior lobe of the thyroid, and thus can be 
permeated by beta radiation from 131I absorbed by the 
thyroid gland. 
It seems worth considering whether this type of 
radiation might lead to any parathyroid malfunction. 
Although the issue has been investigated by various 
researchers, the available conclusions — mostly based 
on a limited number of patients – are often widely 
discrepant or even contradictory [1–4, 6, 10–12]. Some 
authors maintain that radiation from thyroid-absorbed 
131I causes temporary damage to parathyroid glands, 
resulting in their transient hypofunction, whereas 
others, on the contrary, believe that the same radiation 
causes parathyroid hyperfunction [4, 5]. There are also 
studies whose authors claim that the radiation from 
thyroid-absorbed 131I may lead to the development 
of parathyroid adenoma, as well as those which do 
not contain any evidence of increased risk for such 
a development [6–9]. 
For this reason, the purpose of this paper is to assess 
the parathyroid gland function in patients with toxic 
and non-toxic goitres after 131I therapy up to five years 
post-treatment. 
Material and methods 
The sample encompassed 325 patients with benign 
goitres, including 220 patients (180 women and 40 men) 
with toxic nodular goitres (TNG), 80 (70 women and 
ten men) with Graves’ disease (GD), and 25 (22 women 
and three men) with non-toxic nodular goitres 
(NTNG). The average age of the studied population was 
45 ± 10 years. All the patients underwent radioiodine 
(131I) treatment at the Nuclear Medicine Department 
Clinic of the Medical University of Białystok between 
2006 and 2012. The primary aim of the treatment was to 
eliminate hyperthyroidism and/or to reduce the size of 
goitre. Before the administration of therapeutic activity 
of 131I, all the patients were routinely qualified for the 
study: they had undergone physical examination and 
their past medical histories had been investigated. Fur-
ther, the patients’ serum levels of thyroid-stimulating 
hormone (TSH) were measured by means of immuno-
radiometric assay, free thyroxine (fT4) and free triiodo-
thyronine (fT3) were evaluated using the radioimmu-
nological method (RIA). All the nodules were biopsied 
(in order to exclude cancer), USG examinations of the 
thyroid glands were performed, as were 24-hour (T24) 
and 48-hour (T48) radioactive iodine uptake tests and the 
scintigraphic evaluation using a gamma camera (Nu-
clineTM Th, Mediso). Moreover, serum concentrations 
of iPTH were determined by means of the immuno-
chemiluminescence assay (ICMA), the ionised calcium 
method (Ca2+) using ion-selective electrodes, corrected 
for possible pH variations whereas total calcium (Ca) 
and phosphates (P) by means of chemical methods. It 
should be stressed that patients with diseases that might 
affect calcium-phosphorus homeostasis were excluded 
from the study. 
Required therapeutic activity (A) of 131I was calcu-
lated using Marinelli’s formula [10]: 
where 
A — 131I therapeutic activity (MBq) 
25 — unit conversion coefficient 
m — mass of thyroid gland calculated from USG (g) 
D — absorbed dose of 131I (Gy)
T24 — 24-h 131I uptake (%)
Teff  —  effective 131I half-life in thyroid gland (days) = 
= Tbiolog x Tphys/Tbiolog+ Tphys, where Tbiolog
 (rate of iodine 
excretion from the thyroid), Tphys (physical half-life of 
radioactive iodine) 
The choice of thyroid absorbed 131I radiation dose 
depended on the type of hyperthyroidism and was 
consistent with the recommendations made by the 
European Association of Nuclear Medicine [11]. For 
toxic nodular goitre, the absorbed dose was 260Gy, 
for Graves’ disease it was 140Gy, while for non-toxic 
nodular goitre it was 180Gy. 
Throughout the first year following radioiodine 
therapy, all the subjects were re-examined every two 
months, and additionally after three and five years 
post-treatment. The check-ups involved fT3, fT4, TSH, 
iPTH, Ca2+, Ca and P blood serum tests. 
The study was approved by the Ethics Committee 
for Medical Research, Medical University of Bialystok, 
and is in accordance with GCP (good clinical practice). 
Informed consent was given by all patients participat-
ing in the study.
Statistical analysis 
All statistical analyses were performed using the soft-
ware package Statistica 10 (Stat Soft, Tulsa, OK, USA). 
 The Friedman test was used for assessment of the 
differences between pre- and post-treatment levels of 
fT4, fT3, TSH, iPTH,Ca
2+, Ca and P.
The extent to which variations of the thyroid-
absorbed dose of 131I influence the iPTH serum lev-
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Results
Two months after the administration of therapeutic radi-
oiodine, all the patients showed statistically significant (p 
< 0.005) increases in above-normal iPTH serum levels. The 
highest (slightly over two-fold) rise in serum levels of iPTH 
occurred in TNG patients, a little lower — in NTNG ones, 
and relatively the lowest — in GD patients. In the next 
four months, iPTH concentrations remained similarly high 
in all the patients. Six months after radioiodine adminis-
tration, the hormone level started to decrease, to come 
back to normal in the tenth month post-treatment. The 
follow-up examinations — three and five years following 
radioiodine therapy — revealed that the concentrations 
of iPTH, Ca2+, Ca and P did not exceed normal limits in 
any of the patients (Figs. 1 and 2). 
As can be seen from Figure 2, the differences be-
tween blood serum concentrations of Ca2+, Ca and 
P pre- and post-treatment were very small in all the 
patients, and thus statistically insignificant. 
Analysis of iPTH concentrations in the blood se-
rum of patients who underwent radioiodine therapy 
leads to the conclusion that, depending on the thy-
roid absorbed dose, the most significant increase in 
iPTH above the upper normal range (starting from 
the 2nd month post-administration, and persisting 
as long as until the 10th month) occurred in those 
patients whose thyroids absorbed the highest accu-
mulated dose, i.e. 260Gy. With the thyroid absorbed 
dose of 131I at 180Gy, the rise in iPTH above normal 
levels is slightly lower, and its concentration returns 
to normal more rapidly. In thyroids with the lowest 
absorbed dose (140Gy), iPTH levels were found to 
increase to the least extent, and the time necessary for 
achieving normal parameters was the shortest: only 
six months after the administration of 131I. The in-
crease in iPTH was statistically significant at p<0.005 
for all the three absorbed doses (Fig. 3). 
Using the linear regression model, it has been 
proved that there exists a correlation between the ab-
sorbed dose and the level of iPTH, which is expressed 
by the formula below: 
iPTH = 0.54  absorbed dose + 10.24 r2 = 0.97 p < 0.05
From the formula it can be seen that the higher the 
absorbed dose, the greater the rise in the concentration 
of iPTH in blood serum. 
As far as the hormonal function of the thyroid is 
concerned, only TNG patients showed statistically 
significant (p < 0.001) alterations in levels of hor-
mones after radioiodine treatment: mean levels of 
fT3 and fT4 returned from above the upper limit to 
normal as a result of treatment. In all the patients, 
the blood serum levels of fT3 and fT4 remained within 
normal limits for a year following radioiodine admin-
istration, i.e. throughout the period covered by this 
study (Figs. 4 and 5). 
Figure 1. Variations of native parathyroid hormone (iPTH) serum 
levels in patients with TNG, GD and NTNG within one year and 
after 3 and 5 years following radioiodine administration. Part of 
the graph marked by clip corresponds statistically significantly 
(p < 0.05) with elevated iPTH concentrations above normal in 
all patients. (The grey area indicates normal concentrations of 
iPTH in blood serum)
Rycina 1. Zachowanie się stężeń natywnej postaci parathormonu 
(iPTH ) w surowicy krwi u pacjentów z TNG, GD, NTNG 
poddanych radiojodoterapii w okresie do 1 roku oraz po 3 i 5 
latach od podania izotopu. Część wykresu objeta klamrą odpowaida 
istotnie statystycznie (p < 0,05) podwyższonym powyżej normy 
wartościom iPTH u wszystkich pacjentów (Obszar zaznaczony 
szarym kolorem pokazuje zakres norm stężenia PTH w surowicy 
krwi)
Figure 2. Variations of serum levels of A) Ca2+, B) Ca, C) P in 
patients with TNG, GD and NTNG within one year and after 
3 and 5 years following radioiodine administration. (The grey area 
indicates normal concentrations of above factors in blood serum)
Rycina 2. Zachowanie się stężeń A) Ca2+, B) Ca, C) P w surowicy 
krwi u pacjentów z TNG, GD, NTNG poddanych radiojodoterapii 
w okresie do 1 roku oraz po 3 i 5latach od podania izotopu. (Obszar 
zaznaczony szarym kolorem pokazuje zakres norm stężenia Ca2+ 
w surowicy krwi)
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The abovementioned figures prove that the use of 
radioactive isotope of iodine (131I) in the treatment 
of benign thyroid disease (i.e. hyperthyroidism and 
large, euthyreotic goitre) not only normalises hormonal 
function of thyroid but also has an influence on the 
hormonal function of parathyroid glands. In the thera-
peutic process, the transitory hyperparathyroidism was 
observed (independently of the type of hyperthyroid-
ism); however, it usually subsided ten months after ad-
ministration of I-131. A statistically significant increase 
in the level of iPTH in all patients does not change the 
concentrations of calcium and phosphate in the blood.
As in other scientific studies into the issue, our 
sample consisted of patients with thyroid goitres (toxic: 
in the case of TNG and GD, or non-toxic). Before the 
administration of 131I, the concentrations blood serum of 
calcium and iPTH in all our patients were within normal 
limits, as in studies conducted by other authors [4, 5, 13]. 
This makes it possible to conclude that hyperthyroidism 
usually does not affect the levels of calcium and iPTH 
in blood serum. Admittedly, it is an established fact 
that hyperthyroidism may lead to hypercalcaemia (in 
20-30% of hyperthyroid patients), which consequently 
contributes to decreased serum levels of iPTH)[14]. 
Apart from two papers, one by Ross and Nussbaum 
(1985) and the more recent one by Komorovsky and 
Raghavan, the literature does not offer any assessment 
of the early effects of 131I radiation used for the treatment 
of benign thyroid diseases on parathyroid function [4, 
5]. Similarly to Ross and Nussbaum, we observed an 
above normal rise in the levels of iPTH as soon as two 
months post-dose. Nevertheless, our further results and 
their interpretation are markedly different. Ross and 
Nussbaum associated increased iPTH levels with the 
drop in blood serum calcium caused by 131I-induced hy-
pothyroidism, since thyroid hormones have resorptive 
properties and thus, by leading to high bone turnover, 
contribute to higher concentrations of serum calcium. 
They also found that exogenous thyroxine normalises 
the levels of thyroid hormones and TSH, which leads 
to a rise in calcium and a drop in iPTH. Therefore, the 
authors emphasise the impact of the thyroid hormones 
and iPTH on bone metabolism, and thus on the level of 
calcium in the body. Meanwhile, our study showed that 
elevated iPTH did not result from impaired hormonal 
Figure 3. Variations of native parathyroid hormone (iPTH) 
serum levels depending on absorbed dose of 131I in patients 
after radioiodine therapy within one year following radioiodine 
administration. Part of the graph marked by clip corresponds 
statistically significantly(p < 0.05) with elevated iPTH 
concentrations above normal irrespectively of absorbed dose. (The 
grey area indicates normal concentrations of PTH in blood serum)
Rycina 3. Zachowanie się stężeń natywnej postaci parathormonu 
(iPTH )w surowicy krwi w zależności od dawki pochłoniętej 131I 
w tarczycy u pacjentów poddanych radiojodoterapii w okresie do 1 
roku od podania izotopu. Część wykresu objeta klamrą odpowaida 
istptnie statystycznie (p < 0,05) podwyższonym powyżej normy 
wartościom iPTH bez względu na dawkę pochłoniętą (Obszar 
zaznaczony szarym kolorem pokazuje zakres norm stężenia PTH 
w surowicy krwi)
Figure 4. Variations of mean concentrations of fT4 in patients, 
from before radioiodine administration to12 months post-dose. (The 
grey area indicates normal concentrations of fT4 in blood serum)
Rycina 4. Zachowanie się średnich stężeń hormonu fT4 u chorych 
w okresie od momentu przed podaniem radiojodu do 12 miesięcy 
po podaniu. (Obszar zaznaczony szarym kolorem pokazuje zakres 
norm stężenia fT4 w surowicy krwi)
Figure 5. Variations of mean concentrations of fT3 in patients, from 
before radioiodine administration to 12 months post-dose. (The 
grey area indicates normal concentrations of fT3 in blood serum)
Rycina 5. Zachowanie się średnich stężeń hormonu fT3 u chorych 
w okresie od momentu przed podaniem radiojodu do 12 miesięcy 
po podaniu. (Obszar zaznaczony szarym kolorem pokazuje zakres 
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function of the thyroid gland, since in most patients 
treated with radioactive iodine (except several cases of 
GD patients where hormonal supplementation with 
thyroxine was necessary post-therapy), the thyroid 
glands functioned normally. Moreover, elevated iPTH 
levels were observed up to approximately the eighth 
month post-dose, to return to normal limits and remain 
within them until the end of the period covered by this 
study (five years post-dose), with regular thyroid func-
tion throughout the period. Interestingly, the serum 
concentrations of calcium were stable throughout the 
study, in spite of temporary increases in iPTH, even up 
to twice the upper normal limit. Similar stability was ob-
served as far as the serum concentration of phosphates 
was concerned. This is probably because the elevated 
iPTH acted for too short a time, and also because other 
regulatory mechanisms of calcium homeostasis could 
have been involved [15]. The temporary increase in 
iPTH in all our patients can presumably be explained by 
post-radiation inflammation of the parathyroid glands, 
which, in the initial stage, caused excessive release of 
iPTH accumulated in the main parathyroid cells. In 
the next stage, such excessive release continues also as 
a result of the stimulation of the remaining, unde-
stroyed, main cells, which are prompted to hypersecre-
tion of iPTH [16]. We have also noticed that the higher 
the thyroid-absorbed dose of 131I, the greater the impact 
on the parathyroid glands, and the higher the secre-
tion of iPTH due to parathyroid inflammation. Precise 
interdependence between iPTH concentration and 
absorbed dose has been described by means of a linear 
regression model. That is why, in our study, the rise in 
iPTH was the highest in toxic nodular goitre patients, 
who had received the largest absorbed dose, whereas in 
the case of NTNG and GD (where the absorbed doses 
were accordingly lower), the above normal increase in 
iPTH was smaller and the time needed for it to return 
to normal limits was shorter.
It should also be added that not taking into account 
the distribution of the absorbed radiation dose in thy-
roid on parathyroid function was a certain limitation of 
our study. This is due to the fact that a thorough evalu-
ation of the relation between parathyroid function and 
distribution of the absorbed dose of 131I in the thyroid 
gland requires knowledge of the exact location of the 
parathyroid glands. It is widely known that pinpoint-
ing this exact location is very difficult, and in clinical 
practice turns out to be nearly impossible.
Komorovsky and Raghavan describe the case of a 
child suffering from GD who underwent radioiodine 
therapy and, at three months post-treatment, devel-
oped hypocalcaemia [4]. The authors’ conclusions as 
regards the assessment of calcium concentrations in 
patients after 131I therapy aimed at establishing the 
possibility of post-radiation hypoparathyroidism have 
not been confirmed by our data. Perhaps this is due 
to the difference between study samples. Our sample 
consisted of patients whose average age was 45 ± 10, 
while Komorovsky and Raghavan analysed the case 
of a child. 
The majority of other researchers have only ex-
amined the possibility of delayed effects of ionising 
radiation of therapeutic 131I on the adjacent para-
thyroid glands. So any comparisons between those 
studies and ours are far more difficult and must, to 
a large extent, be based on assumptions. Our research 
was concluded after a five-year observation period 
of the hormonal function of parathyroid glands after 
radioiodine administration. Throughout that time, 
apart from elevated iPTH levels in the first months 
post-dose, no abnormalities were discovered in either 
the hormonal function of the parathyroid glands or 
the serum concentrations of ionised calcium. Notwith-
standing the first ten months post-treatment, we can 
agree with the authors who have studied late effects 
of radiation (some of them describe patients at 35 
years post-dose) that radioiodine therapy for benign 
thyroid disease does not affect the parathyroid func-
tion [6, 7, 17]. Mortensen et al. chose an interesting 
methodology to assess the secretory function of the 
parathyroid glands after radiation [7]. They emphasise 
that merely measuring iPTH serum levels is not suf-
ficient for adequate assessment of the glands’ function. 
Additional stimulation tests are necessary to examine 
the secretory reaction of the parathyroids to a phar-
macologically achieved decrease in ionised calcium 
levels by using EDTA, which binds to calcium. Also 
these authors concluded that radioiodine radiation 
does not alter the parathyroid function. 
It is also necessary to mention those authors who 
have conducted research among patients treated (up 
to over a decade prior to studies) for benign thyroid 
diseases with ionising radiation and found evidence for 
increased likelihood of parathyroid adenoma in those 
cases [13, 18, 19]. In addition, Colaco claims that the risk 
of parathyroid adenoma grows with age [8]. 
To sum up, one must bear in mind that in order 
to determine the cause of hyperparathyroidism, it is 
essential to consider whether a patient’s past medical 
history includes radioiodine therapy. It seems that this 
thesis will be an important factor that aims at improving 
the diagnosis of hyperparathyroidism. 
Conclusions
 — Radioactive iodine therapy for benign thyroid dis-
eases contributes to temporary (up to ten months 
post-treatment) hyperparathyroidism. 
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 — The resultant above normal iPTH levels in the blood 
serum of treated patients does not significantly af-
fect the concentration of calcium and phosphates 
in the body. 
 — Above normal increase in serum iPTH has a positive 
correlation with thyroid absorbed dose of radioac-
tive iodine. 
 — In the diagnostic process, radioiodine therapy 
should be taken into consideration as one of the 
potential causes of hyperparathyroidism. 
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